Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV401D)

• Drug Name: Debio-0824 Drug Info
• Synonyms: Shk-192; ShK analogs (Subcutaneous formulation, autoimmune disease), Kineta; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease); Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (Subcutaneous formulation, autoimmune disease), Airmid; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitor (injectable peptide, autoimmune disease), Davis; Stichodactyla helianthus-derived Kv1.3 potassium channel inhibitors (injectable peptide, autoimmune disease), Kineta One

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Phase 1b/2a	[1]
Psoriatic arthritis	FA21	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMV401D

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated potassium channel Kv1.3 (KCNA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dalazatide	DMJ1NG4	Inclusion body myositis	4A41.2	Phase 1b/2a	[4]
UK-78282	DMKBILF	Inflammation	1A00-CA43.1	Terminated	[5]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[6]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one	DMKMH5L	Discovery agent	N.A.	Investigative	[7]
2-Methoxy-N-(3-methyl-2-phenyl-butyl)-benzamide	DM31E6J	Discovery agent	N.A.	Investigative	[8]
correolide	DMACH7K	Discovery agent	N.A.	Investigative	[9]
Correloid	DM5ISQK	Discovery agent	N.A.	Investigative	[10]
CP-339818	DMTJOWH	Discovery agent	N.A.	Investigative	[5]
5-(4-Phenylbutoxy)psoralen	DM3QFCV	Discovery agent	N.A.	Investigative	[11]
[1-Benzyl-1H-quinolin-(4E)-ylidene]-hexyl-amine	DMH3BG5	Discovery agent	N.A.	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated potassium channel Kv1.3 (KCNA3)	TTY3UE6	KCNA3_HUMAN	Inhibitor	[3]

References

• [1] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [2] ClinicalTrials.gov (NCT02446340) Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers. U.S. National Institutes of Health.
• [3] Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease. J Pharmacol Exp Ther. 2012 September; 342(3): 642-653.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3. J Med Chem. 2001 Apr 12;44(8):1249-56.
• [6] Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
• [7] Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. 2005 Nov;68(5):1254-70.
• [8] Benzamide derivatives as blockers of Kv1.3 ion channel. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1161-4.
• [9] Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry. 1999 Apr 20;38(16):4922-30.
• [10] Potent Kv1.3 inhibitors from correolide-modification of the C18 position. Bioorg Med Chem Lett. 2005 Jan 17;15(2):447-51.
• [11] Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol. 2004 Jun;65(6):1364-74.
• [12] Novel inhibitors of potassium ion channels on human T lymphocytes. J Med Chem. 1995 May 26;38(11):1877-83.